Which pharma companies are ready for diagnostic integration in 2017? | Diaceutics

Which pharma companies are ready for diagnostic integration in 2017?

April 4th, 2017

The regular Pharma Readiness reports produced by Diaceutics aim to capture a snapshot of the diagnostic and precision medicine industries at certain times in a fast-evolving landscape. Pharma Readiness for Diagnostic Integration 2017 is no exception and discusses such vital topics as:

  • Trends, best practice and preferred organizational styles in diagnostics (Dx) and precision medicine (PM)
  • Therapies in the pipeline
  • The impact of pharma readiness and financial risks
  • The companies that are pushing forward
  • Key takeaways and predictions

Production of this year’s report involved analysing 23 main pharma companies and the PM credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy assets. The benchmarking process is continually being refined to provide the most important industry insights. New analytical additions for 2017 include:

  • Analysis of therapy portfolios which are highly Dx-enabled, for example, hepatitis and diabetes
  • Scoring companies’ internal capability according to our “Like it/Learn it/Leverage it” to reflect with more granularity the impact of organizational structures on commercial performance
  • Inclusion of Big Data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of PM beyond molecular testing
  • Ranking of real-time experience with test launches

Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. So in addition to concise predictions around segmentation, partnering, the role of laboratories and Dx-enablement strategies, the 2017 report also contains a series of specially commissioned opinion pieces looking at the key trends likely to shape the pharma/Dx interface and PM marketplace to 2020 and beyond.

For an informed view of the current diagnostic landscape, the companies forging ahead and a look ahead at future trends, download Pharma Readiness for Diagnostic Integration 2017.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn